In the past week, MXCT stock has gone up by 9.86%, with a monthly gain of 26.94% and a quarterly surge of 17.78%. The volatility ratio for the week is 6.83%, and the volatility levels for the last 30 days are 6.81% for MaxCyte Inc The simple moving average for the past 20 days is 7.66% for MXCT’s stock, with a 11.25% simple moving average for the past 200 days.
Is It Worth Investing in MaxCyte Inc (NASDAQ: MXCT) Right Now?
There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MXCT is 97.35M, and at present, short sellers hold a 3.25% of that float. The average trading volume of MXCT on January 10, 2025 was 533.75K shares.
MXCT) stock’s latest price update
MaxCyte Inc (NASDAQ: MXCT) has experienced a rise in its stock price by 4.34 compared to its previous closing price of 4.38. However, the company has seen a gain of 9.86% in its stock price over the last five trading days. globenewswire.com reported 2024-12-23 that ROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxCyte’s growth and strategic direction. Upon Mr. Mandell’s retirement, MaxCyte will have nine directors.
Analysts’ Opinion of MXCT
Many brokerage firms have already submitted their reports for MXCT stocks, with Craig Hallum repeating the rating for MXCT by listing it as a “Buy.” The predicted price for MXCT in the upcoming period, according to Craig Hallum is $7 based on the research report published on November 29, 2023 of the previous year 2023.
MXCT Trading at 18.90% from the 50-Day Moving Average
After a stumble in the market that brought MXCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.58% of loss for the given period.
Volatility was left at 6.81%, however, over the last 30 days, the volatility rate increased by 6.83%, as shares surge +9.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.01% upper at present.
During the last 5 trading sessions, MXCT rose by +9.86%, which changed the moving average for the period of 200-days by +3.39% in comparison to the 20-day moving average, which settled at $4.24. In addition, MaxCyte Inc saw 9.86% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MXCT starting from Johnston John Joseph, who sale 3,000 shares at the price of $4.01 back on Dec 26 ’24. After this action, Johnston John Joseph now owns 141,950 shares of MaxCyte Inc, valued at $12,021 using the latest closing price.
Johnston John Joseph, the Affiliate of MaxCyte Inc, proposed sale 12,000 shares at $4.11 during a trade that took place back on Dec 26 ’24, which means that Johnston John Joseph is holding shares at $49,320 based on the most recent closing price.
Stock Fundamentals for MXCT
Current profitability levels for the company are sitting at:
- -1.02 for the present operating margin
- 0.79 for the gross margin
The net margin for MaxCyte Inc stands at -0.78. The total capital return value is set at -0.2. Equity return is now at value -16.00, with -13.87 for asset returns.
Currently, EBITDA for the company is -44.13 million with net debt to EBITDA at 0.44. When we switch over and look at the enterprise to sales, we see a ratio of 10.16. The receivables turnover for the company is 10.0for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.81.
Conclusion
In summary, MaxCyte Inc (MXCT) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
